ABSTRACT
【Objective】 To observe the application of the traditional and modified catheter transfer method in leukocyte-depleted blood preparation and the effect of modified method on reducing the blood discard rate due to hot joint leakage. 【Methods】 After leucocyte filtration, the traditional method is to seal the product bag catheter directly and then connect the whole blood catheter, while the modified method is to seal the two sections on the product bag catheter and then connect the whole blood catheter at the distal seal. The blood discard rates of the two methods due to the hot joint leakage in the catheter connection of leukocyte reduction were analyzed. 【Results】 After repeated training for the staff, using the same type of equipment, the blood discard rate due to heat sealing leakage by modified method was 0(0/33 595), significantly lower than that by traditional method(0.11%, 36/32 873, P<0.001). 【Conclusion】 The modified method can significantly reduce the discard rate of blood due to seal leakage and save valuable blood resources. However, there is still a risk of seal leakage, and staff should take preventive measures against occupational exposure
ABSTRACT
Nampt/Visfatin/PBEF is a primary, rate-limiting enzyme involved in NAD+ biosynthesis, which serves as a pivotal substance for proteins, and is required for cell growth, survival, DNA replication and repair and energy metabolism. Growing researches have elucidated that it is a pleiotropic protein that functions not only as an enzyme, but also as an adipocytokin, a growth factor, and a cytokine. Additionally, accumulated evidences indicate that Nampt is correlated to various malignant tumors, and complicated mechanisms are proposed to be involved in the carcinogenesis, progression, invasion and metastasis of it, including regulation of energy metabolism and genome instability, promotion of proliferation, angiogenesis, and tumor-promoting inflammation, resistance in cell death and avoidance of immune destruction. APO866 and CHS-828 are recognized inhibitors of Nampt, known to block the intracellular and extracellular NAD+ synthesis pathway. Both of them are currently in clinical trials for the treatment of various malignant tumors and have been shown to represent novel promising antitumor chemotherapeutic agents.